Aquestive Therapeutics Reports Q3 Financial Results

November 3, 2026 - 18:48

(AP) - Aquestive Therapeutics Inc. on Tuesday announced a loss of $16 million for the third quarter. This financial setback highlights ongoing challenges for the company as it navigates a competitive landscape in the pharmaceutical industry. The loss reflects a decrease in revenue compared to the same period last year, raising concerns among investors about the company's future prospects.

The company attributed the decline to various factors, including increased operational costs and ongoing investments in research and development. Despite the financial hurdles, Aquestive remains focused on advancing its pipeline of innovative therapies aimed at addressing unmet medical needs. The management expressed optimism about upcoming product launches and potential partnerships that could bolster revenue in the coming quarters.

As the company continues to work through these challenges, stakeholders will be closely monitoring its strategic initiatives and financial performance in the months ahead. The road to recovery may be long, but Aquestive is determined to turn its vision into reality.